PMID- 36093105 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20220913 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 13 DP - 2022 TI - Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study. PG - 951570 LID - 10.3389/fendo.2022.951570 [doi] LID - 951570 AB - OBJECTIVE: To study the effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on glucose metabolism and abdominal fat distribution in patients with obesity and type 2 diabetes mellitus (T2DM). METHODS: From April 30, 2020, to April 30, 2022, a prospective randomized controlled study was carried out at the Endocrinology Department of Beijing Hospital, the National Center of Gerontology. According to the in- and exclusion criteria and by the random table method, revisited T2DM patients were selected as the research subjects and were allocated into a Study group (taking liraglutide) and a Control group (underwent lifestyle interventions). All patients received continuous 12-weeks interventions to the endpoint, and the changes of value [Delta=(endpoint)-(baseline)] of physical measurements, blood tests, the energy spectrum CT examination results, and body composition analysis results were analyzed and compared. RESULTS: A total of 85 people completed this study, and among them, 47 were in the Study group and 38 were in the Control group. Compared with the Control group, the changes of hemoglobin A1c (HbA1c) level (-0.78 +/- 1.03% vs. -1.57 +/- 2.00%, P=0.025), visceral fat area (0.91 +/- 16.59 cm(2) vs. -7.1 +/- 10.17 cm(2), P=0.011), and subcutaneous fat area of abdomen [0 (-18.75, 15.5) cm(2) vs. -16.5 (-41.75, -2.25) cm(2), P=0.014] were all greater in the Study group. The adverse events caused by liraglutide were mainly concentrated in the gastrointestinal system and all of them were minor adverse events. CONCLUSION: Liraglutide can be the drug of choice for weight management and reduction of abdominal fat distribution in patients with obesity and T2DM. CI - Copyright (c) 2022 Yu, Zou, Pan, Song, Li, Zhang, Zhou, Wang and Guo. FAU - Yu, Dongni AU - Yu D AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zou, Mingzhu AU - Zou M AD - Department of Radiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Pan, Qi AU - Pan Q AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Song, Yan AU - Song Y AD - Department of Radiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Miao AU - Li M AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Xianbo AU - Zhang X AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhou, Yan AU - Zhou Y AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Xiaoxia AU - Wang X AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Guo, Lixin AU - Guo L AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20220826 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 0 (Hypoglycemic Agents) RN - 839I73S42A (Liraglutide) SB - IM MH - *Diabetes Mellitus, Type 2/complications/drug therapy MH - Humans MH - Hypoglycemic Agents/pharmacology MH - Intra-Abdominal Fat/diagnostic imaging MH - Life Style MH - *Liraglutide/pharmacology MH - Obesity/complications/drug therapy MH - Prospective Studies MH - Tomography, X-Ray Computed PMC - PMC9458907 OTO - NOTNLM OT - abdominal fat distribution OT - diabetes OT - liraglutide OT - obesity type 2 diabetes mellitus OT - type 2 diabetes COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/13 06:00 MHDA- 2022/09/14 06:00 PMCR- 2022/01/01 CRDT- 2022/09/12 04:26 PHST- 2022/05/24 00:00 [received] PHST- 2022/07/29 00:00 [accepted] PHST- 2022/09/12 04:26 [entrez] PHST- 2022/09/13 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2022.951570 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2022 Aug 26;13:951570. doi: 10.3389/fendo.2022.951570. eCollection 2022.